The Three-Parent Precedent: What Mitochondrial Donation Teaches Britain About Heritable CRISPR

A question Britain has already answered once

Discussions of heritable genome editing in the UK frequently proceed as though the country has never crossed this line. It has. Since 2015, in tightly defined circumstances, British clinics have been licensed to create embryos containing genetic material from three people, and in 2023 the Human Fertilisation and Embryology Authority confirmed that a small number of children had been born in the UK as a result.

That matters for the argument now taking shape around CRISPR. Mitochondrial donation is heritable: the mitochondrial DNA a child receives will be passed to subsequent generations. The distinction the 2015 regulations drew was not between heritable and non-heritable modification, but between mitochondrial and nuclear DNA. It is a defensible distinction — but it is a line in a particular place, not the absence of a line.

Understanding how that line was drawn, and by whom, is the most useful preparation available for the harder conversation that improved editing tools will force.

What is lawful today

In the UK, research on human embryos is permitted under licence up to fourteen days of development. Modification of nuclear DNA in embryos created for treatment is not. The Human Fertilisation and Embryology Act 1990, substantially amended in 2008, prohibits the use in treatment of embryos whose genetic material has been altered, with a narrow exception created by secondary legislation for mitochondrial donation.

This architecture is important. Heritable nuclear editing is not simply unregulated in Britain; it is illegal, and the prohibition rests in primary legislation. Any move to permit it would require Parliament to act, not merely a regulator to issue guidance. That is a higher barrier than most jurisdictions have erected, and it is deliberate.

The 2015 regulations themselves passed after years of scientific review, three separate public consultations and a free vote in both Houses. Licences are granted case by case to named clinics, for named patients, with long-term follow-up requirements. The Newcastle centre that holds the licence operates under conditions that would strike most researchers as unusually strict. That is the point.

Why the mitochondrial case was, in some respects, the harder one

It is tempting to assume mitochondrial donation was the gentler precursor to germline editing. The reverse may be closer to the truth.

Mitochondrial replacement is technically demanding, involves the creation and disposal of embryos, and was opposed by those who regarded it as a step onto a slope rather than a solution to a narrow problem. It required Parliament to accept that a child could have genetic connections to three people — a proposition with real cultural and ethical weight. It advanced because the clinical need was specific, the affected group small, the disease severe, the alternatives absent, and the scientific review unusually thorough.

Critically, the intervention changes a component of the cell that does not encode identity, appearance or aptitude in any meaningful sense. Mitochondria produce energy. This is why the ethical case could be made in terms of avoiding devastating disease rather than in terms of improvement.

Where CRISPR diverges

Heritable CRISPR editing does not share that tidy boundary. Editing nuclear DNA touches the genes that shape physiology broadly. The technical case for it — correcting a pathogenic variant in an embryo where preimplantation genetic testing cannot find an unaffected embryo — is genuine but narrow. The widening of possibilities beyond that case is precisely what concerns regulators.

The tools have also become easier. Base editing and prime editing have improved precision and reduced reliance on double-strand breaks, and the clinical success of somatic editing has normalised the idea that editing human DNA is a routine medical act. Normalisation is not the same as justification, but it changes the political weather.

Three issues would dominate any serious assessment.

First, safety across generations. Off-target edits may not manifest for decades, and long-term follow-up of children born following mitochondrial donation is itself still in its early years. A regulatory framework that cannot track outcomes for fifty years is not really evaluating the intervention it licenses.

Second, mosaicism and control. Editing an embryo is not editing a cell line. Unintended outcomes are embodied in a person who cannot consent to them.

Third, scope. Mitochondrial donation was legislated for one indication with a clear clinical rationale. Nuclear editing would arrive without such a natural boundary, and the difference between treating disease and enhancing traits in an embryo is easier to state in a committee room than to fix in statute.

What the HFEA and public dialogue would need to address

If the UK ever revisits the prohibition, several questions would need answers before legislation rather than after it.

Is the HFEA the right regulator for a decision of this kind, or does it require a dedicated body with a wider membership? What would meaningful public dialogue look like, given that the 2012–13 mitochondrial donation consultations were unusually extensive and still attracted criticism for their framing? How would the views of disabled people and patient groups be weighted, rather than consulted? What international coordination is realistic when the Third International Summit on Human Genome Editing, held in London in 2023, demonstrated how divergent national positions remain?

And, most awkwardly: what is the threshold? Which condition, which severity, which absence of alternatives would justify a licence? The mitochondrial framework answered that question narrowly and in advance. A heritable editing framework would need to answer it in the abstract, which is a far less comfortable exercise.

A caution that is also an asset

The Nuffield Council on Bioethics concluded in 2018 that heritable genome editing could be ethically acceptable in some circumstances, provided it was regulated and consistent with the welfare of the future person. That report was widely read as permissive. It was also, read carefully, a statement about how high the bar should be.

Britain's cautious history cuts both ways. It demonstrates that this country can legislate on uncomfortable biological questions without panic, and that its institutions can hold a line for years under pressure. It also demonstrates how much scrutiny a narrow intervention attracted, and how hard won the 2015 regulations were.

Any government contemplating heritable CRISPR would inherit both the precedent and the burden. On current evidence, that inheritance is more likely to be an advantage than an obstacle — provided the memory of how mitochondrial donation was argued is kept intact, rather than reduced to a talking point about three-parent babies.